Krukenberg Tumor

• Krukenberg Tumor is a rare metastatic ovarian cancer, typically originating from gastric cancer.
• Symptoms are often non-specific, including abdominal pain, distension, and weight loss, making early detection challenging.
• Diagnosis involves imaging, tumor marker tests, and definitive biopsy, which reveals characteristic signet-ring cells.
• Treatment is complex, often involving a combination of surgery, chemotherapy, and sometimes targeted therapies, depending on the primary cancer.
• Prognosis is generally poor due to its advanced stage at diagnosis and aggressive nature.

What is a Krukenberg Tumor?

Krukenberg Tumor refers to a malignant tumor in the ovary that has metastasized from a primary cancer site elsewhere in the body, rather than originating in the ovary itself. While various primary cancers can lead to a Krukenberg Tumor, the most common source is gastric adenocarcinoma, accounting for approximately 70-90% of cases. Other potential primary sites include the colon, breast, appendix, and biliary tract. These tumors are characterized histologically by the presence of mucin-filled signet-ring cells within a cellular stroma, which are distinct from primary ovarian cancers. They represent a small fraction of all ovarian tumors, estimated to be between 1% and 2% globally (Source: World Journal of Surgical Oncology, 2017 review on Krukenberg tumor).

Symptoms, Causes, and Diagnosis

The presentation of Krukenberg tumor symptoms and signs can be varied and often non-specific, making early diagnosis challenging. Patients may experience symptoms related to the ovarian mass itself, such as abdominal pain, distension, bloating, or a palpable abdominal mass. Other systemic symptoms, often indicative of advanced cancer, include unexplained weight loss, loss of appetite, and fatigue. In some cases, ascites (fluid accumulation in the abdomen) or menstrual irregularities may occur.

The primary causes of Krukenberg tumor are the metastatic spread of cancer cells from a primary tumor, most frequently from the stomach. The exact mechanism of metastasis is debated but is thought to involve transcoelomic spread (cancer cells shedding into the peritoneal cavity and implanting on the ovarian surface), lymphatic spread, or hematogenous (bloodstream) dissemination. The rich lymphatic supply and hormonal environment of the ovaries are believed to make them a favorable site for metastatic implantation.

Diagnosis of Krukenberg Tumor typically involves a multi-modal approach. Initial evaluation may include a physical examination, imaging studies, and tumor marker tests. Definitive diagnosis requires a tissue biopsy.

• Imaging: Ultrasound, CT scans of the abdomen and pelvis, and MRI are crucial for identifying ovarian masses and assessing the extent of disease, including the primary tumor site.
• Tumor Markers: Elevated levels of CA-125, CEA, or CA 19-9 may be observed, though these are not specific to Krukenberg Tumor.
• Biopsy: Histopathological examination of tissue, usually obtained through laparoscopy or laparotomy, reveals the characteristic mucin-filled signet-ring cells, confirming the metastatic nature.

Treatment of Krukenberg Tumor

The Krukenberg tumor diagnosis and treatment strategy is complex and highly individualized, depending on the primary cancer site, the extent of metastasis, and the patient’s overall health. Given that these tumors are metastatic, treatment often focuses on managing advanced disease and improving quality of life.

Treatment options may include:

• Surgery: Cytoreductive surgery, which aims to remove as much of the tumor as possible, including both ovarian masses and the primary tumor if feasible, can be considered. The goal is to reduce tumor burden, alleviate symptoms, and potentially improve the effectiveness of systemic therapies.
• Chemotherapy: Systemic chemotherapy is a cornerstone of treatment, often administered before (neoadjuvant) or after (adjuvant) surgery, or as a primary treatment for unresectable disease. The choice of chemotherapy regimen is typically guided by the histology and origin of the primary tumor.
• Targeted Therapy and Immunotherapy: For certain primary cancers, targeted therapies or immunotherapies may be considered if specific molecular markers are identified. These treatments aim to block specific pathways involved in cancer growth or enhance the body’s immune response against cancer cells.
• Palliative Care: For patients with advanced or widespread disease, palliative care is essential to manage symptoms, control pain, and support the patient’s and family’s well-being.

The prognosis for Krukenberg Tumor is generally poor, primarily because it represents an advanced stage of metastatic cancer. Survival rates vary significantly based on the primary tumor site, the extent of metastasis, and the patient’s response to treatment. Early detection of the primary cancer before ovarian metastasis occurs offers the best chance for improved outcomes.